• Je něco špatně v tomto záznamu ?

Exploration of Neusilin® US2 as an Acceptable Filler in HPMC Matrix Systems-Comparison of Pharmacopoeial and Dynamic Biorelevant Dissolution Study

T. Bílik, J. Vysloužil, M. Naiserová, J. Muselík, M. Pavelková, J. Mašek, D. Čopová, M. Čulen, K. Kubová

. 2022 ; 14 (1) : . [pub] 20220105

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22010323

Grantová podpora
MUNI/A/1574/2020 Masaryk University

Modern pharmaceutical technology still seeks new excipients and investigates the further use in already known ones. An example is magnesium aluminometasilicate Neusilin® US2 (NEU), a commonly used inert filler with unique properties that are usable in various pharmaceutical fields of interest. We aimed to explore its application in hypromellose matrix systems (HPMC content 10-30%) compared to the traditionally used microcrystalline cellulose (MCC) PH 102. The properties of powder mixtures and directly compressed tablets containing individual fillers NEU or MCC, or their blend with ratios of 1.5:1, 1:1, and 0.5:1 were investigated. Besides the routine pharmaceutical testing, we have enriched the matrices' evaluation with a biorelevant dynamic dissolution study and advanced statistical analysis. Under the USP apparatus 2 dissolution test, NEU, individually, did not provide advantages compared to MCC. The primary limitations were the burst effect increase followed by faster drug release at the 10-20% HPMC concentrations. However, the biorelevant dynamic dissolution study did not confirm these findings and showed similarities in dissolution profiles. It indicates the limitations of pharmacopoeial methods in matrix tablet development. Surprisingly, the NEU/MCC blend matrices at the same HPMC concentration showed technologically advantageous properties. Besides improved flowability, tablet hardness, and a positive impact on the in vitro drug dissolution profile toward zero-order kinetics, the USP 2 dissolution data of the samples N75M50 and N50M50 showed a similarity to those obtained from the dynamic biorelevant apparatus with multi-compartment structure. This finding demonstrates the more predictable in vivo behaviour of the developed matrix systems in human organisms.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22010323
003      
CZ-PrNML
005      
20220425131807.0
007      
ta
008      
220420s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/pharmaceutics14010127 $2 doi
035    __
$a (PubMed)35057023
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Bílik, Tomáš $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, 61200 Brno, Czech Republic $1 https://orcid.org/0000000153301542
245    10
$a Exploration of Neusilin® US2 as an Acceptable Filler in HPMC Matrix Systems-Comparison of Pharmacopoeial and Dynamic Biorelevant Dissolution Study / $c T. Bílik, J. Vysloužil, M. Naiserová, J. Muselík, M. Pavelková, J. Mašek, D. Čopová, M. Čulen, K. Kubová
520    9_
$a Modern pharmaceutical technology still seeks new excipients and investigates the further use in already known ones. An example is magnesium aluminometasilicate Neusilin® US2 (NEU), a commonly used inert filler with unique properties that are usable in various pharmaceutical fields of interest. We aimed to explore its application in hypromellose matrix systems (HPMC content 10-30%) compared to the traditionally used microcrystalline cellulose (MCC) PH 102. The properties of powder mixtures and directly compressed tablets containing individual fillers NEU or MCC, or their blend with ratios of 1.5:1, 1:1, and 0.5:1 were investigated. Besides the routine pharmaceutical testing, we have enriched the matrices' evaluation with a biorelevant dynamic dissolution study and advanced statistical analysis. Under the USP apparatus 2 dissolution test, NEU, individually, did not provide advantages compared to MCC. The primary limitations were the burst effect increase followed by faster drug release at the 10-20% HPMC concentrations. However, the biorelevant dynamic dissolution study did not confirm these findings and showed similarities in dissolution profiles. It indicates the limitations of pharmacopoeial methods in matrix tablet development. Surprisingly, the NEU/MCC blend matrices at the same HPMC concentration showed technologically advantageous properties. Besides improved flowability, tablet hardness, and a positive impact on the in vitro drug dissolution profile toward zero-order kinetics, the USP 2 dissolution data of the samples N75M50 and N50M50 showed a similarity to those obtained from the dynamic biorelevant apparatus with multi-compartment structure. This finding demonstrates the more predictable in vivo behaviour of the developed matrix systems in human organisms.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vysloužil, Jakub $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, 61200 Brno, Czech Republic $1 https://orcid.org/0000000151423191
700    1_
$a Naiserová, Martina $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, 61200 Brno, Czech Republic
700    1_
$a Muselík, Jan $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, 61200 Brno, Czech Republic
700    1_
$a Pavelková, Miroslava $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, 61200 Brno, Czech Republic $1 https://orcid.org/0000000185228343
700    1_
$a Mašek, Josef $u Department of Pharmacology and Toxicology, Veterinary Research Institute, 62100 Brno, Czech Republic $1 https://orcid.org/0000000167888487
700    1_
$a Čopová, Drahomíra $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, 61200 Brno, Czech Republic
700    1_
$a Čulen, Martin $u Department of Chemistry, Faculty of Pharmacy, Masaryk University, 61200 Brno, Czech Republic
700    1_
$a Kubová, Kateřina $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, 61200 Brno, Czech Republic $1 https://orcid.org/0000000249702084
773    0_
$w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 14, č. 1 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35057023 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220420 $b ABA008
991    __
$a 20220425131805 $b ABA008
999    __
$a ind $b bmc $g 1784552 $s 1161521
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c 1 $e 20220105 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
GRA    __
$a MUNI/A/1574/2020 $p Masaryk University
LZP    __
$a Pubmed-20220420

Najít záznam

Citační ukazatele

Možnosti archivace